Intrauterine adhesions (IUA) are fibrotic scars that develop within the uterine cavity, often following surgical interventions or infections. The resulting condition, widely referred to as Asherman’s ...

BEDFORD, Mass.--(BUSINESS WIRE)--Rejoni, Inc., a privately held clinical-stage company, today announced the completion of enrollment of 150 patients in the Juveena Hydrogel pivotal clinical study.

Chinese researchers have demonstrated new reconstructable uterus-derived materials (RUMs) that allow almost complete recovery from severe uterine injury. Relevant results were published online in ...

The FDA gave premarket approval to the first medical device for the treatment of women with symptomatic moderate-to-severe intrauterine adhesions, known as Asherman syndrome, maker Womed announced on ...

Credit: Womad. The Womed Leaf consists of a proprietary polymer that is inserted into the uterine cavity immediately after completion of a hysteroscopic adhesiolysis procedure. The device is indicated ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced the publication ...

Asherman syndrome is a rare gynecological condition that causes adhesions to form in the uterus. Your risk of developing this rare condition increases if you have had a D and C procedure. Asherman ...

Rejoni, Inc., a privately held clinical-stage company, today announced the completion of enrollment of 150 patients in the Juveena Hydrogel pivotal clinical study. This announcement marks a ...